Evidence map›Paper›PMID 37901245›Full record

ArticleFrontiers in immunology2023

Vancomycin-induced gut microbial dysbiosis alters enteric neuron-macrophage interactions during a critical period of postnatal development.

Ellen Merrick Schill, Elisabeth L Joyce, Alexandria N Floyd, Sreeram Udayan, Brigida Rusconi, Shreya Gaddipati, Bibiana E Barrios, Vini John, Mitchell E Kaye, Devesha H Kulkarni and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ellen Merrick SchillDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Elisabeth L JoyceDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Alexandria N FloydDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Sreeram UdayanDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Brigida RusconiDivision of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.
Shreya GaddipatiDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Bibiana E BarriosDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Vini JohnDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Mitchell E KayeDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Devesha H KulkarniDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Jocelyn T PautaDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Keely G McDonaldDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Rodney D NewberryDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Washington University in St. Louis · US

Funding

Washington University DDRCC Supplemental Equipment RequestP30DK052574 · NIDDK · WASHINGTON UNIVERSITY · PI Jeffrey Wade Brown · 2000 to 2026
$30.8M
Training of the Pediatric Physician-ScientistT32HD043010 · NICHD · WASHINGTON UNIVERSITY · PI MARK E. LOWE · 2002 to 2026
$6.4M
Pediatric Gastroenterology Research Training ProgramT32DK077653 · NIDDK · WASHINGTON UNIVERSITY · PI PHILLIP I TARR · 2007 to 2026
$5.8M
GOBLET CELLS IN INTESTINAL IMMUNE HOMEOSTATSISR01DK097317 · NIDDK · WASHINGTON UNIVERSITY · PI NEWBERRY, RODNEY D · 2012 to 2025
$5.6M
Immune interactions with commensal microbes in early lifeR01AI173220 · NIAID · WASHINGTON UNIVERSITY · PI CHYI S HSIEH, Rodney D Newberry · 2023 to 2026
$2.8M
Gut Intrinsic Inflammatory ResponsesU01AI163073 · NIAID · WASHINGTON UNIVERSITY · PI HSIEH, CHYI S, NEWBERRY, RODNEY D · 2021 to 2025
$2.6M
Microbial drivers of metabolically unhealthy obese phenotypeK01DK133670 · NIDDK · WASHINGTON UNIVERSITY · PI Devesha Kulkarni · 2022 to 2026
$839k
S1P as regulator of neonatal mucosal immune development and injuryK01DK125606 · NIDDK · WASHINGTON UNIVERSITY · PI RUSCONI, BRIGIDA AGNESE · 2020 to 2024
$679k
NIAID NIH HHS R01 AI173220NIAID NIH HHS U01 AI163073NICHD NIH HHS T32 HD043010NIDDK NIH HHS K01 DK125606NIDDK NIH HHS K01 DK133670NIDDK NIH HHS P30 DK052574NIDDK NIH HHS R01 DK097317NIDDK NIH HHS T32 DK077653
6 · The paper itself

Abstract

Vancomycin is a broad-spectrum antibiotic widely used in cases of suspected sepsis in premature neonates. While appropriate and potentially lifesaving in this setting, early-life antibiotic exposure alters the developing microbiome and is associated with an increased risk of deadly complications, including late-onset sepsis (LOS) and necrotizing enterocolitis (NEC). Recent studies show that neonatal vancomycin treatment disrupts postnatal enteric nervous system (ENS) development in mouse pups, which is in part dependent upon neuroimmune interactions. This suggests that early-life antibiotic exposure could disrupt these interactions in the neonatal gut. Notably, a subset of tissue-resident intestinal macrophages, muscularis macrophages, has been identified as important contributors to the development of postnatal ENS. We hypothesized that vancomycin-induced neonatal dysbiosis impacts postnatal ENS development through its effects on macrophages. Using a mouse model, we found that exposure to vancomycin in the first 10 days of life, but not in adult mice, resulted in an expansion of pro-inflammatory colonic macrophages by increasing the recruitment of bone-marrow-derived macrophages. Single-cell RNA sequencing of neonatal colonic macrophages revealed that early-life vancomycin exposure was associated with an increase in immature and inflammatory macrophages, consistent with an influx of circulating monocytes differentiating into macrophages. Lineage tracing confirmed that vancomycin significantly increased the non-yolk-sac-derived macrophage population. Consistent with these results, early-life vancomycin exposure did not expand the colonic macrophage population nor decrease enteric neuron density in CCR2-deficient mice. Collectively, these findings demonstrate that early-life vancomycin exposure alters macrophage number and phenotypes in distinct ways compared with vancomycin exposure in adult mice and results in altered ENS development.

Indexed as

Gastrointestinal MicrobiomeSepsisAnimalsAnti-Bacterial AgentsDysbiosisMacrophagesMiceNeuronsVancomycinAnti-Bacterial AgentsVancomycinearly life antibioticsenteric nervous systemmonocyte recruitmentmuscularis macrophageneonatal dysbiosis

Identifiers

PMID37901245
PMCPMC10602895
OpenAlexW4387581230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.